It has inked a co-promotion agreement with Bausch Health Companies to for NeutraSal to oncology customers in the US.
In exchange for its efforts, Midatech will receive a percentage of the net sales. The financial terms of the agreement are undisclosed.
Common cancer side-effect
The product is prescribed for Xerostomia, also known as dry mouth syndrome, which is a common side-effect of cancer treatment.
"NeutraSal provides oncology professionals with an effective therapy for patients suffering from Xerostomia, which can be a painful and debilitating side effect of certain cancer therapies,” said David Benharris, president of Midatech’s US business.
He pointed synergies will be derived by selling a broader range of oncology products. “The addition of NeutraSal to our portfolio appreciably enhances our offering of effective treatment options to provide continuity of care for patients suffering from the side effects of cancer therapies," he explained.